Characterising TRIB1 Nanobodies using a Yeast Surface Display Platform with Flow Cytometry by Whitta, Saffron Tian Grelyntan













Characterising TRIB1 Nanobodies using a 













A thesis submitted in partial fulfilment of the Degree of 
Bachelor of Biomedical Science with Honours. 







The mammalian tribble (TRIB) pseudokinase family has three homologues, which act as an 
adaptor protein to regulate cell signalling pathways. TRIB proteins can bind the E3 ligase, 
Constitutive Photomorphogenesis Protein 1 (COP1), allowing TRIB regulatory function over 
essential proteins via the ubiquitin (Ub)-proteasomal pathway. For example, TRIB can cause 
the degradation of the transcription factor C/EBP-α which, regulates the differentiation of 
haematopoietic cells and adipocytes. TRIB also regulates critical signalling pathways such as 
the mitogen-activated protein kinase (MAPK) and serine/threonine-specific protein kinase 
(Akt) pathways, that controls mitosis, cell differentiation and survival. With different TRIB 
activities, TRIB proteins have various conformations with its substrates. Dysregulation of 
TRIB expression has been related to some cancer pathology such as Acute Myeloid 
Leukaemia (AML) and adenocarcinoma; however, the full molecular mechanism of how 
TRIB leads to pathogenesis is yet understood. 
Single-domain antibodies called, nanobodies (Nbs), currently show promise in 
furthering discoveries in protein function and structure due to their ability to stabilise protein 
conformations with their small size of ~15 kDa, which allows; Nbs the ability to bind smaller 
epitopes that conventional antibodies are incapable of doing, and Nbs to be expressed 
intracellularly. Therefore, it is hypothesised that TRIB-specific Nbs as a research tool, may 
be used to discover further TRIB proteins’ functional mechanisms that lead to the pathology 
of cancers. Understanding how TRIB-substrate conformations link with its cell signalling 
consequences, may reveal new therapeutic avenues. 
Focusing on TRIB1 alone, TRIB1-specific Nbs previously screened from the 
McMahon Library, were expressed on the surface of the cell walls of S. cerevesiae (yeast). 
This allowed for the use of flow cytometry to characterise TRIB-1 Nbs affinity and 
specificity to its target based on the mean fluorescence intensity of the labelled Nbs and 
TRIB proteins: This flow cytometry method was able to be used to obtain a binding affinity 
(KD = 315 nM) similar to isothermal titration calorimetry (KD  = 366 nM) for our positive 
TRIB1-Nb binding control, Nb2.011. Results showed that none of the eight TRIB1-Nbs 
tested had better affinities to TRIB1 than Nb2.011 (KD > 366 nM). Although no promising 
TRIB1-Nbs was identified from the library samples, this project did elucidate limitations and 
important considerations in the use of the yeast surface display system, for the rapid, initial 
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characterisation screening of TRIB-Nbs after panning a Nb library for potential binders at 
nanomolar concentrations. Overall, we were able to conclude that this method of Nb 
characterisation, using a yeast display system with flow cytometry, may improve the 
discovery pipeline of TRIB-Nbs by narrowing down the panel of potential Nbs with desirable 
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1.1 Introduction to Tribble (TRIB) Pseudokinase. 
The Tribble (TRIB) protein family was first discovered in Drosophila melanogaster and later 
discovered in humans. In Drosophila flies, only one TRIB homologue exists, and its function 
was first discovered to coordinate cell division and proliferation during morphogenesis 
necessary for mesoderm formation, by inducing proteasomal degradation of Cdc25 (M-phase 
inducer) activators String and Twine (Grosshans and Wieschaus, 2000; Mata et al., 2000; 
Seher and Leptin, 2000). The human TRIB pseudokinase family, unlike in Drosophila, 
comprises of three homologues (TRIB1, TRIB2, and TRIB3). Within human tribbles, 
sequence identity lies at 71.3% between TRIB1/2, 53.3% between TRIB1/3, and 53.7% 
between TRIB2/3 (Yokoyama and Nakamura, 2011).  
Unlike canonical kinases that can regulate substrate activity through phosphorylation, 
TRIB proteins have obtained atypical residues which makes them unable to regulate efficient 
phosphoryl-transfer from adenosine triphosphate (ATP) to substrates (Bailey et al., 2015; 
Foulkes et al., 2018). Instead, TRIB proteins indirectly modulate various signalling pathways 
as an adaptor protein. Most studied are the mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) pathway, the Protein kinase B (PKB or 
Akt - a serine/threonine-specific protein kinase) pathway, and CCAT-enhancer-binding 
protein (C/EBP) pathway, which is involved in cell growth, cell survival and cell 
differentiation (Chen et al., 2018; Eyers, 2015; Eyers et al., 2017; Mashima et al., 2014; 
Ohoka et al., 2005). Non-homeostatic expression of TRIB proteins has therefore been 
associated with the pathogenesis of diseases such as cancer. 
As TRIB proteins can associate with multiple substrates and induce various cellular 
outcomes, TRIB proteins are assumed to have a high degree of structural plasticity that give 
rise to multiple, transient complexes. However, this makes functional research on TRIB 
proteins difficult, as to understand the mechanisms underlying TRIB-related pathology, an 
understanding of the different TRIB protein complexes and how it relates to cell signalling 
events is required. Hence, new research tools are required to study further the TRIB family 
structure and how this relates to its various functional outcomes.  
1.2 The TRIB Pseudokinase Domain. 
TRIB proteins cannot phosphorylate substrates like regular kinases and have evolved to 
become regulatory scaffold proteins. Despite all three human TRIB homologues showing 
residual ability to bind ATP by retaining key lysine residues seen in kinases (Figure 1.2.1.A – 
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in red, the β3 lysine residue is shown to be conserved), they have no functional kinase 
activity (Lohan and Keeshan, 2013). Unlike canonical kinases, human TRIB homologues 
lack specific sequences needed for phosphoryl transfer, and this gives rise to their ‘pseudo’ 
kinase domain (Yokoyama and Nakamura, 2011). The DFG (Asp-Phe-Gly) motif in kinases, 
that acts to orient ATP into the binding site, is replaced in TRIB proteins (Eyers et al., 2017; 
Jamieson et al., 2018; Lohan and Keeshan, 2013). In TRIB1/2, the DFG motif is replaced by 
an SLE (Ser-Leu-Glu) sequence (Figure 1.2.1.A – highlighted DFG motif in red is not seen in 
human TRIB proteins), which stabilises the activation loop blocking the ATP binding pocket 
(Jamieson et al., 2018; Murphy et al., 2015). Furthermore, human TRIBs lack the necessary 
sequence for sufficient ATP binding (GXGX2GXV/’glycine-rich’ motif in subdomain 1) and 
also lacks the HRD (His-Arg-Asp) residue that transfers the phosphate group from ATP to 
the substrate in the catalytic cleft (Bailey et al., 2015; Lohan and Keeshan, 2013). In short, 
human TRIBs lack the necessary sequences found in kinase proteins, summarised in Figure 
1.2.1.A, that allows functional and optimal phosphoryl-transfer to substrates. 
 
Figure 1.2.1: The TRIB pseudokinase domain. A.  Adapted from (Eyers, 2015), functional kinase 
sequences, highlighted in red, are lost in TRIB pseudokinases (unable to phosphorylate substrates). In 
TRIB1/2, the DFG motif that act to orient ATP into the binding site, is replaced by the SLE motif that 
stabilises the activation loop to act as an autoinhibitory structure of COP1 binding when a substrate is 
not bound, shown in Figure 1.2.1.B.  B. A protein structure of the TRIB1 pseudokinase domain 
(UniProt ID: Q96RU8) obtained from (Jamieson et al., 2018), shows how the activation loop (in 
green) conforms when substrate binds to expose the COP1 motif. 
1.3 TRIB signalling pathways. 
TRIB proteins have distinct motifs that facilitate different signalling modulation. As a family 
of pseudokinases, TRIB proteins acquired distinct amino acid sequences/motifs that allow 
scaffolding of effector proteins to their substrates. Site-directed mutagenesis has shown that 
an ILLHPW motif in the C-lobe of all TRIB homologues’ pseudokinase domain, is what 
allows docking and upregulation of phosphorylating MEK proteins (dual-specificity tyrosine 
and serine/threonine kinases) in the MAPK pathway (Eyers et al., 2017; Jin et al., 2007; 
Yokoyama et al., 2010). Another conserved motif is the DQxVPx (generally DQLVPE) motif 
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in the C-terminal tail of all three TRIB homologues, which allows the recruitment of the E3 
ligase, Constitutive Photomorphogenesis Protein 1 (COP1). Coupled with TRIB proteins 
having a degron (degradation signalling sequence) binding site in the pseudokinase domain, 
that may recruit the degrons of substrate proteins such as CEBPα and acetyl-coenzyme A 
carboxylase (ACC), TRIB proteins can regulate protein function via the ubiquitin (Ub)-
proteasomal degradation pathway (Dedhia et al., 2010; Eyers et al., 2017; Keeshan et al., 
2010).   
A solved crystal structure of human TRIB1 pseudokinase domain has shown that substrate 
(e.g. C/EBPα) binding to the TRIB degron in the pseudokinase domain, leads to folding of 
the activation loop toward the αC-helix which allows for the COP1 motif to be released from 
the autoinhibitory conformation facilitated by the SLE motif (refer to Figure 1.2.1.A-B) 
(Jamieson et al., 2018). Subsequently, COP1 can bind to the C-terminal tail of TRIB proteins. 
As the COP1 motif is tethered to the N-lobe of the pseudokinase domain, TRIB proteins can 
scaffold COP1 to substrates bound at the pseudokinase domain (Dedhia et al., 2010); This 
induces poly-ubiquitylation of the substrate at a distinct lysine residue (K48) which marks it 
for 26S proteasomal degradation. Summarily, the distinct motifs and its position along the 
TRIBs’ protein structure for MEKs (C-lobe of pseudokinase domain) and COP1 (tethered to 
the N-lobe of the pseudokinase domain) (Figure 1.3.1), allows for different protein 
regulations. With TRIB proteins being able to associate with multiple substrates, TRIB exists 
in different conformations (only one conformation has been solved, Figure 1.2.1.B), which 
may be better studied using nanobodies that can stabilise them. 
TRIB can act as a tumour suppressor or oncogenic factor by modulating the activity of MEK 
and Akt. As a tumour suppressor, TRIB2/3 interact with Akt to reduce its activation by 
mTORC2 (rapamycin-insensitive protein complex 2) phosphorylation (in the case of TRIB3) 
(Salazar et al., 2014). The direct mechanism of this Akt modulation is still yet established for 
all TRIB homologues  (refer to Figure 1.3.1) (Eyers et al., 2017). This suppression of Akt 
activity by TRIB proteins is linked to an increase in FOXO (forkhead family of transcription 
factors) and BH3-only protein BCL-2 associated agonist of cell death (BAD) which promotes 
apoptosis (Salazar et al., 2014; Tsuzuki et al., 2019; Zareen et al., 2013). However, this 
tumour suppressing role of TRIB proteins with Akt modulation is contradictory to TRIB’s 




Figure 1.3.1: A brief view of the human Tribble signalling pathway. LHS: Schematic adapted 
from (Eyers et al., 2017) showing TRIB proteins’ signalling interactions, the variable PEST domain 
that makes TRIB proteins unstable, and the distinct C-terminal motifs;  ILLHPW allows TRIB direct 
interaction with MEKs increasing MAPK pathway signalling; DQLVPE allows TRIB to act as an 
adaptor, facilitating E3 ligase (e.g. COP1) to contact its protein target bound to the TRIB 
pseudokinase domain. TRIB homologues also modulate the Akt signalling pathway – the mechanism 
is yet fully known; however, TRIB3 is suggested to modulate mTORC2 phosphorylation of AKT. 
RHS: The dotted arrows show an example of  COP1-mediated degradation of a substrate; the 
example substrate shown is C/EBPα p42. Degradation C/EBPα p42 leads to loss of differentiation in 
myeloid cells that can lead to acute myeloid leukaemia. LHS: left-hand side. RHS: right-hand side. 
This figure was made using BioRender. 
As previously stated, MEK binds TRIB proteins to the ILLHPW motif in the C-lobe. MEK 
binding to TRIB has been shown to increase the phosphorylation of ERK proteins and 
subsequently, cell survival and growth (Jin et al., 2007). Preventing ERK phosphorylation by 
inhibiting MEK1 (using UO126), showed there was a correlation between decreased 
phosphorylated-ERK concentration and significantly reduced TRIB-induced C/EBP 
degradation (Yokoyama et al., 2010). ERK1/2 has been shown to phosphorylate C/EBP, 
which upregulate its degradation. C/EBP is a transcription factor that drives the 
differentiation of myeloid cells and adipocytes. Upregulated degradation of the C/EBP then 
compounds the oncogenic effects of TRIB-MEK interaction, that increases the likelihood of 
oncogenesis. Subsequently, TRIB proteins’ contradictory role in maintaining cell 
homeostasis may suggest exclusive MEK or AKT modulation at a given time: Understanding 
TRIB allostery/conformations may be the key to deciphering its multifaceted role in cell 
homeostasis and the development of TRIB-related human cancers. 
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1.4 TRIB association with human cancers. 
TRIB homologue expression levels occur inversely in cells. TRIB proteins are generally 
associated with myeloid-derived cells due to its relationship with the C/EBP family of 
transcription factors; however, it is also expressed in other cells types. It has been speculated 
that TRIB proteins regulate each other’s expressions through negative and feedforward 
mechanisms (Rishi et al., 2014; Salomé et al., 2018). TRIB1/3 and TRIB2  mRNA 
(messenger ribonucleic acid) are inversely expressed in different blood cell lineages under 
normal conditions: Myeloid-derived cells express high levels of TRIB1/3 and low levels of 
TRIB2, whereas lymphoid derived cells express high levels of TRIB2 and low levels of 
TRIB1/3 (Salomé et al., 2018). This differential expression (inverse correlated TRIB1-TRIB2 
and proportional TRIB1-TRIB3 expression) may conditionally pertain to other cells. In 
HepG2 (immortalised human liver carcinoma) cells, insulin stimulation increased TRIB1 and 
TRIB3 mRNA expression but reduced TRIB2 mRNA expression (Tsuzuki et al., 2019). A 
general trend has been seen that TRIB1 and TRIB3 mRNA are expressed in inverse 
proportion to TRIB2 mRNA. 
TRIB1/2 overexpression is linked to the development of Acute Myeloid Leukaemia 
(AML). Non-homeostatic levels of TRIB1/TRIB2 within myeloid cells, lead to dysplasia that 
can pathologically result in (AML) (Jackson and Taylor, 2002). Under pathologic conditions, 
murine models with transfected haemopoietic stem cells (Dedhia et al., 2010) and mRNA 
analysis of human AML cells (Salomé et al., 2018), show that some AML subtypes may be 
attributed to overexpression of either TRIB1 or TRIB 2. An RT-PCR (reverse transcription 
polymerase chain reaction) study has shown that 8q24 amplification in AML cells, not only 
increased MYC (Proto-Oncogene, BHLH Transcription Factor) mRNA expression but also 
TRIB1 when compared to healthy donor cells (Röthlisberger et al., 2007). Overexpression of 
TRIB1/2 reduces the cellular concentration of the full (p42) C/EBPα isoform and increases 
levels of the truncated (p30) C/EBPα isoform (refer to Figure 1.3.1 - RHS) (Keeshan et al., 
2006). The literature agrees that C/EBPα p30 increase in haematopoietic stem cells may be a 
key driver for AML development, as it lacks the N-terminus transactivation domain (present 
in C/EBPα p42) that prevents cell cycle progression in its mitotic stage via E2F (E2 
transcription factor) regulation (Rishi et al., 2014). Although transient overexpression of 
TRIB1/2 has been found to act as tumour suppressors by upregulating apoptosis through 
inhibiting JNK and the proceeding dephosphorylation of BCL-2 (apoptosis regulatory 
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protein) on residue Ser70 (Gilby et al., 2010), it may stand that constitutive TRIB1/2 
overexpression does induce leukemogenesis. 
In adenocarcinoma, low expression of TRIB3 is linked to evasion of apoptosis. TRIB3 
research has revealed its involvement in the endoplasmic reticulum (ER) stress response 
downstream of ER stress sensors (Ohoka et al., 2005), that may directly be regulated by 
TRIB1 (Mashima et al., 2014). Although both TRIB1 and TRIB3 affect the ER stress 
response, TRIB3 expression, unlike TRIB1 and TRIB2, has no significant contribution to the 
pathogenesis of blood cancers but in adenocarcinoma (Dedhia et al., 2010). Unlike most 
TRIB1/2-related cancers, TRIB3 mRNA levels are disproportionately expressed to the degree 
of cancer lesions in breast carcinoma (BT474) and hepatocellular carcinoma (HepG2) 
(Salazar et al., 2014). Furthermore, unlike the overexpression seen in TRIB1/2-related 
cancers that confers advantageous upregulation of MAPK pathway, TRIB3 expression in 
adenocarcinoma is downregulated for reduced stress-induced apoptosis (Ohoka et al., 2005). 
TRIB3 overexpression studies in neurons have proven its pro-apoptotic effects by 
downregulating Akt phosphorylation which decreases dephosphorylation of FOXO proteins 
(Aimé et al., 2015; Zareen et al., 2013); in dopaminergic neurons of the substantia nigra, 
TRIB3 overexpression does increase cell death occurrences as it reduces pro-survival protein 
Parkin (Aimé et al., 2015). It is unknown how or why TRIB3 has a bias in Akt regulation 
over MAPK regulation (seen in TRIB1/2), and how TRIB3’s tumour suppressing activity is 
reduced through underexpression in adenocarcinoma. 
PEST domain may be the key to sustained overexpression or under expression of TRIB 
proteins in diseases such as cancer. TRIB proteins are hard to research, not only because of 
the difficulty present in isolating its different transient complexes as it interacts with its 
different substrates: Each of the homologues have an N-terminal PEST domain (a peptide 
sequence rich of proline, glutamic acid, serine and threonine that signals for protein 
degradation) with distinct motifs, that gives it varying short intracellular half-lives (Eyers et 
al., 2017).  The difference in TRIB protein turnover in normal and diseased conditions may 
then determine the duration of effects seen, e.g. increased MEK phosphorylation with longer 
active TRIB compared with more transient TRIB presence, generating more extensive cell 
survival and mitotic events that contribute to gaining cancer hallmarks like resistance to cell 
death. Imaging the half-lives of TRIB protein homologues in vitro and being able to trap the 
multiple transient conformations of TRIB proteins as it acts with its substrates, may be useful 
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to prove whether the PEST domain is an important feature in TRIB homeostasis and TRIB-
related diseases. 
1.5 Prospects of using nanobodies in potentiating human TRIB research. 
Nanobodies are emerging to be a useful research tool. Derived from camelid antibodies, 
Nbs consist of only two variable heavy chains (Vhh) and lack the light-heavy chains of 
conventional antibodies (refer to Figure 3). Therefore, the antigen-binding sites of 
nanobodies are not fragmented between two variable light and heavy chains, and Nbs can 
easily be expressed in the cytoplasm of bacteria (E. coli) and yeast (S. cerevesiae) (Desmyter 
et al., 2015; Hassanzadeh-Ghassabeh et al., 2013). Nanobodies are also resistant to oxidative 
changes, having no significant change in antigen affinity with reduced disulphide bonds, as 
well as reduced thermostability at 47 °C (Pleiner et al., 2015). These characteristics make 
Nbs an easy to reproduce, useful research tool. Being approximately 15 kDa (kilodaltons) in 
size, Nbs can bind smaller epitopes with nanomolar affinity, which conventional antibodies 
(~150 kDa) are incapable of doing (Desmyter et al., 2015). It has the ability to provide 
stability to G-coupled protein receptors (GPCRs) and their different allosteric states, allowing 
for the discovery that a heterogeneous mechanism lies with how agonists may induce variable 
biological responses according to which transient converting receptor states become 
stabilised with substrate interaction (Staus et al., 2016). Hence, using Nbs to trap TRIB 
conformations may potentiate the understanding of the human TRIBs-protein interactions and 
how this relates to its various functional outcomes. Despite the possible uses for Nbs in TRIB 
research, no TRIB-Nbs have yet to be fully developed for research use. 
Figure 1.5.1: Conventional antibodies vs Camelid derived nanobodies. Nanobodies consists of 
only heavy chains (light purple blocks) and are small (~15 kDa), unlike conventional antibodies that 
are big (~150kDa) and consist of two heavy chains and two light chains (magenta blocks). This figure 
was made using BioRender. 
Nanobodies may allow profiling of TRIB function in cells. Whilst some literature has 
found evidence that overexpression of TRIB proteins is present in subtypes of cancer (Dedhia 
et al., 2010; Mashima et al., 2014), there are some studies that have found TRIB expression 
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to decrease (Ohoka et al., 2005; Salazar et al., 2014). Despite there being no clarity in what 
determines TRIB proteins as a tumour suppressor or as an oncogenic factor, related 
oncogenic stimuli that increase TRIB expression may result in increased or suppressed 
mitotic ability in cancer cells, that is dependent on the context of cell type and status of other 
cancer-related genes (Röthlisberger et al., 2007; Yokoyama et al., 2010). Most TRIB study 
done is limited to observing TRIB mRNA expression without confirming protein presence, 
and looks indirectly at TRIB protein interaction through cell morphogenesis or 
phosphorylation of its downstream effectors like ERK and Akt (Dedhia et al., 2010; Salazar 
et al., 2014; Salomé et al., 2018). The development of specific Nbs for TRIB proteins will 
therefore facilitate further study of; TRIB1/2 protein expression within myeloid and 
lymphoid derived cells and its association to AML through C/EBP regulation, the non-
redundant function between TRIB homologue expressions in different cell types, as well as 
more in-depth structural analysis on TRIB conformations that determine its tumour 
suppressor/oncogenic role (MAPK or Akt modulating bias) under homeostatic and diseased 
states (Ohoka et al., 2005; Salazar et al., 2014). 
In recent years, a new screening method using flow cytometry have been developed where 
synthetic Nbs may be expressed on the surface of yeast cells via an Aga1p-Aga2p tether or 
Aga1p-Aga2p mimicking tether (Feldhaus et al., 2003; McMahon et al., 2018; Uchański et 
al., 2019); The use of conjugated fluorophores to Nbs and proteins of interest (POI), allows 
for flow cytometric visualisation of Nb affinity and specificity to POIs, generating results that 
are equivalent to previous antibody screening methodologies such as surface plasmon 
resonance (Michael et al., 2003). Using this method may improve the discovery pipeline for 
TRIB-specific Nbs. 
1.6 Aims 
The discovery and use of TRIB-specific Nbs may potentiate further human TRIB studies and 
reduce the gap in knowledge for understanding the contradictory roles of TRIB as a tumour 
suppressor and an oncogenic factor in diseased states. Therefore, with a focus on the initial 
development of human TRIB1-Nbs, this project will utilise a yeast surface display system 
and aim to: 
1. Optimise the flow cytometric analysis of the yeast surface display system to 
characterise TRIB1-Nbs. 
2. Characterise the affinity and specificity of TRIB1-Nbs. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Bacterial Strains and Plasmids 
Table 2.1.1 1: Bacterial Strains 
Strain Description 
BL21(DE3) Escherichia coli. fhuA2 [ion] ompT gal [dcm]ΔhsdS 
MC1061 Escherichia coli. araD139, Δ(ara, leu)7697, ΔlacX74, galU-, galK-, 
hsm+, strA 
Table 2.1.1.2: Plasmids. His6 fusion tag was used in this study. 
Insert Vector backbone Resistance 
Long TRIB1 - M62784-372 LIC N-terminal His6 tag Kanamycin (Kan) 
Long TRIB2 – M92453-343 LIC N-terminal His6 tag Kan 
2.1.2 Yeast Strain and Nanobody Clones 
In this study, Nb2.011 which has been shown to co-elute and co-crystalise with TRIB1 is 
used as a positive control. Whereas Nb5.018 (a Nb known to bind PPTrap – an unrelated, 
membrane bound protein), is used as a negative control for Nb-binders. Table 2.1.2.2 
summarises the Nbs characterised in this study, using the yeast display system and flow 
cytometry. 
Table 2.1.2.1: Yeast Strain. The common Brewer’s Yeast strain BJ5465 was used in this study, for 
surface Nb expression. 
Strain Description 
BJ5465 Saccharomyces cerevisiae. MATα ura352 trp1 leu2Δ1 
his3Δ200 pep4::HIS3 prb1Δ1.6 R can1 GAL 
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Table 2.1.2.2: Nanobody Clones used in this project. The TRIB1 Nb clones (S. cerevesiae, refer to 
Table 2.1.2.1) used in this study, was previously generated, and screened against its target protein by 
the Mace Lab, as specified by the McMahon yeast display screening method (McMahon et al., 2018). 











































2.1.3 Media for bacterial cell culture 
Bacterial cell culture media was prepared with type 1 deionised water (18.2 MΩ) from a 
Milli-Q Advantage A10 academic water purification system (Millipore). Media was then 
autoclaved at 121 °C, 0.1 MPa for 20 minutes. Escherichia coli strains were grown in Terrific 
Broth (TB) media (FORMEDIUM, for protein expression), Lysogeny Broth (LB) media 
(FORMEDIUM, for DNA plasmid amplification) or on LB agar (colony growth). LB media 
was made of 10 g peptone, 10 g NaCl and 5 g yeast extract per Litre: 7.5 g of agar was added 
per 500 mL, for LB agar. TB media was made of 12 g tryptone and 24 g of yeast extract per 
Litre. Supplementation of media with Kanamycin (50 μg/mL) was done before use.  
2.1.4 Media for yeast cell culture 
All yeast cell culture media was prepared with type 1 deionised water (18.2 MΩ) from a 
Milli-Q A10 academic water purification system (Millipore). Media was then autoclaved at 
121 °C, 0.1 MPa for 20 minutes. Saccharomyces cerevisiae nanobody clones were grown in 
Yglc4.5-Trp media (pH 4.5) until stationary phase, which consisted of (per 1 Litre); 3.8 g Trp 
drop-out media supplement (Kaiser), 6.7 g yeast nitrogen base w/out amino acids 
(FORMEDIUM), 10.4 g tri-sodium citrate dihydrate (SCHARLAU), 7.4 g citric acid 
monohydrate (Fisher Chemical). Yglc4.5-Trp media was then supplemented with 1% 
Penicillin/Streptavidin (Pen/Strep) antibiotic (10,000 units/mL stock, Gibco), and 10% 
sterifiltered D-glucose (20% stock solution, FORMEDIUM). Saccharomyces cerevisiae Nb 
clones were induced to express Nbs in yeast-Trp media (pH 6) which consisted of (per 1 
Litre); 3.8 g Trp drop-out media supplement (FORMEDIUM), 6.7 g yeast nitrogen base 
w/out amino acids (FORMEDIUM). Yeast-Trp media was then supplemented with 1% 
Pen/Strep and 10% of sterifiltered D-glucose (20% stock solution) or 10% sterifiltered D-




Except where otherwise stated, buffers and solutions were made up with type 1 deionised 
water (18.2 MΩ) from a Milli-Q Advantage A10 academic water purification system 
(Millipore). Chromatography buffers were filtered with a 0.45 μm vacuum filter and degassed 
for ~20 minutes. Yeast selection buffers were filtered with a 0.45 μm Sterifilter (Corning), 
and yeast glucose/galactose supplements was syringe-sterifiltered with a 0.2 μm Sterifilter 
(Corning). 
Table 2.1.5.1: Solutions and its ingredients used in this study. 
Solutions Ingredients 
Cell freezing buffer 20 mM Tris (pH 8.0), 300 mM NaCl 
Standard purification buffer 50 mM Tris (pH 8.0), 300 mM NaCl, 10% sucrose 
(w/v), 10% glycerol (v/v), 10 mM imidazole 
Elution buffer 50 mM Tris (pH 8.0), 300 mM NaCl, 10% sucrose 
(w/v), 10% glycerol (v/v), 300 mM imidazole 
Size exclusion chromatography 
buffer 
20 mM HEPES (pH 7.6), 150 mM NaCl 
Resolving buffer (for SDS-
PAGE) 
1.5 M Tris (pH 8.8) 
Stacking buffer (for SDS-
PAGE) 
0.5 M Tris (pH 6.8) 
2x SDS-sample buffer 4% (w/v) SDS, 125 mM Tris (pH 6.8), 0.01% (w/v) 
bromophenol blue, 100 mM DTT, 20.4% glycerol 
10x SDS-PAGE running buffer 1% SDS, 192 mM glycine, 25 mM Tris (pH 8) 
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Coomassie stain 50% (v/v) ethanol, 10% (v/v) glacial acetic acid, 0.25% 
(w/v) Coomassie brilliant blue R250 
SDS-PAGE de-stain 50% (v/v) ethanol, 10% (v/v) glacial acetic acid 
Standard selection buffer 150 mM NaCl, 20 mM HEPES (pH 7.6), 0.1% (w/v) 
BSA, 5 mM maltose 
2.1.6 Fluorophores 
Table 2.1.6.1: Fluorophores used in this study for flow cytometry.  
Fluorophores Excitation/Emission Wavelength (nm) 
Mouse monoclonal [16B12] to HA tag 
conjugated to PE (ab72479, abcam) 
488/575 
FITC, general α-protein (Pierce FITC Antibody 
Labelling Kit, Thermo Scientific) 
494/518 
2.2 Methods  
2.2.1 Bacterial cell culture techniques 
2.2.1.1 Bacterial transformation 
Competent BL21 (DE3) cells (for protein expression), or MC1061 cells (for DNA cloning), 
were transformed by incubating 20 μL of cells with 0.5 μL of plasmid. First, cells were 
incubated on ice for 10 minutes, followed by a 45 second heat shock at 42 °C. Cells were 
placed back on ice for 2 minutes before the addition of 350 μL of LB media. Cells were then 
incubated for 45 minutes in a 37 °C shaker, before being spread on LB agar plates bearing 
Kan antibiotic. Plates were incubated at 37 °C overnight.  
2.2.1.2 Protein and DNA expression 
For protein expression, cell plates transformed in Section 2.2.1.1, were resuspended with 3 
mL of LB for 1 L cultures. In 1 L cultures, 1 mL of antibiotics and 1 mL of resuspended cells 
were added. Cells were grown at 37 °C on a shaker, until the optical density at 600 nm 
(OD600) reached 0.5-0.8. Cultures were moved to an 18 °C shaker and left to acclimatise for 
45 minutes. Expression was then induced with 20 μL of isopropyl β-D-1-
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thiogalactopyranoside (final concentration of 0.2 mM) per 100 mL of culture. Protein 
expression was left to occur overnight. 
For DNA expression, one colony from the cell plates transformed in Section 2.2.1.1, was 
extracted, and grown overnight in 3 mL LB media, at 37 °C on a shaker. Cells were harvested 
the following day in 1.7 mL microcentrifuge tubes and pelleted using a HERAEUS Pico17 
centrifuge (Thermo Scientific) at 13 rpm, for 2 minutes.  A Zyppy™ plasmid miniprep kit 
(Zymo Research) was then used to purify DNA plasmids from bacterial cultures. The 
Zyppy™ plasmid miniprep protocol was altered to include the resuspension of cells in 1 mL 
of water following centrifugation of the 3 mL overnight culture. Fourty microlitres of DNase-
free water was used to elute DNA plasmids; DNA was then stored at -20 °C. 
One L cultures were harvested in 1 L centrifuge bottles using the Avanti JXN-26 centrifuge 
(Beckman Coulter) and the JA-17  rotor at 25,000 rpm for 30 minutes at 4 °C. Supernatant 
was discarded, and cell pellets were resuspended in 10 mL of freeze buffer (Table 2.1.5.1). 
Resuspended cells were then frozen at -20 °C, until required.  
2.2.1.3 Bacterial cell lysis 
For 1 L cultures, resuspended cells were thawed at room temperature and made up to 30 mL 
with standard purification buffer. DNase and lysozyme were each added to final 
concentrations of 3 μg/mL and 0.8 mg/mL, respectively. Cells were emulsified using an 
Avestin Emulsiflex C3 (ATA Scientific), following the manufacturer’s instructions; samples 
were lysed through homogenisation with a high-pressure valve at ~15,000 psi.  
2.2.1.4 Ni2+ affinity purification 
Protein constructs expressed (1 L culture) had a His6 tag, therefore, were purified using Ni
2+ 
affinity purification. A 5 μL sample was collected from the initial cell lysate as an insoluble 
fraction. This sample was pelleted at 10,000 rpm for 2 mins. Post centrifugation, 5 µL of 
supernatant was kept as a soluble fraction. The remaining supernatant was loaded onto 2 mL 
His-select Ni2+ affinity resin (Sigma), pre-equilibrated with purification buffer. A 50 mL tube 
with mixed resin/supernatant was left to bind on a rotator at 4 °C, for 30 minutes. The resin 
was then transferred to a Poly-Prep Chromatography handheld-column (BioRad). Samples 
were washed with purification buffer and a 5 μL flow through sample was kept. Protein was 
eluted with 300 mM of imidazole in purification buffer; 4x 1 mL elutions were taken for 1 L 
cultures. Eluted protein concentrations were measured using the NanoDrop (Section 2.2.2.2). 
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Pooled elution fractions were incubated overnight at 18 °C with 5 μL 3C protease and 0.2% 
DTT, for the removal of the His6 tag. The soluble, insoluble, flow through, post His6 tag  
removal, and elution fractions from Ni2+ affinity chromatography were then analysed by 
SDS-PAGE (Section 2.2.2.1). 
2.2.1.5 Size exclusion chromatography (SEC) 
Elution fractions from Ni2+ affinity purification were pooled and concentrated further, to 
~500 μL in an ultrafiltration concentrator (PALL) with a 10 kDa molecular weight cut-off 
filter. Protein was loaded onto a Superdex™ S200 size exclusion column (GE Healthcare), 
pre-equilibrated with SEC buffer. Size exclusion chromatography was performed using an 
ÄKTA pure chromatography system (GE Healthcare), where SEC buffer was run through the 
column at a flow rate of ~0.5 mL/min and 500 μL fractions were collected. A real-time 
chromatogram of 280 nm absorbance was used to predict protein concentrations and mass 
was compared to proteins of known size run on the same Superdex™ S200 column. To 
confirm purification of proteins of interest, fractions of eluted proteins were then analysed 
using SDS-PAGE, followed by analysis on the nanodrop. Samples were snap frozen using 
liquid nitrogen and stored at -80 °C. 
2.2.2 General protein techniques 
2.2.2.1 SDS-PAGE 
Proteins expressed and extracted from E. coli BL21 cells were separated for analysis, using 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE 
gradient gels were made using a gradient former (Model 385, BioRad) and a peristaltic pump 
(Pharmacia). Low (10%) and high (20%) percentage-acrylamide gel solution reagents, plus 
the stacking gel reagents are found in Table 2.2.2.1. Gradient gels were poured and set, 
before the stacking buffer was added. A 15-well comb was inserted into this stacking gel to 
create wells for sample loading. 
Table 2.2.2.1: SDS-PAGE gradient gel reagents. 
High % gel 
40% acrylamide 15 mL 
Resolving buffer 7.5 mL 
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MQ water 1.82 mL 
10% SDS 300 μL 
Bromophenol blue 210 μL 
TEMED 15 μL 
10% APS 150 μL 
Low % gel 
40% acrylamide 7.5 mL 
Resolving buffer 7.5 mL 
MQ water 14.54 mL 
10% SDS 300 mL 
TEMED  15 μL 
10% APS 150 μL 
Stacking gel 
40% acrylamide 3.75 mL 
Resolving buffer 7.77 mL 
MQ water 18 mL 
Bromophenol blue 10 μL 
TEMED 25 μL 




Protein samples were diluted in 2x SDS-PAGE sample buffer (Table 2.1.5.1). Soluble and 
insoluble fractions obtained from bacterial cell culture lysates, were boiled at 95 °C for 5 
minutes and briefly spun down. Three microlitres of Precision Plus Protein Marker (BioRad) 
was loaded into the first lane and 5-10 μL of diluted samples were loaded into separate wells 
of the gel. Gels were run with an Electrophoresis Power Supply (EPS-600, Pharmacia) at 220 
V for 45 minutes with water cooling. Gels were stained for ~15 minutes in Coomassie Blue 
and destained overnight. The processed gels were imaged with an Image Scanner III (GE 
Healthcare). 
2.2.2.2 Protein quantification using NanoDrop 
Protein concentrations (bacterial cell culture) were quantified using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific). The absorbance of protein solutions at 280 nm was 
measured using a 1 μL sample. Extinction coefficients for each protein construct was 
previously calculated by inputting amino acid sequences into ExPASy ProtParam; this was 
used to calculate protein concentration using Beer-Lambert law.  
2.2.3 Yeast cell culture techniques 
Yeast cell culture techniques were performed under sterile conditions in the presence of an 
open flame. During recovery, growth, and induction of yeast cells, the 24 well blocks used 
for culture were covered with sterile BS25 Aera Seal (Excel Scientific Incorporated). 
2.2.3.1 Recovery of yeast Nb clones 
Previously, the Mace Lab had built a TRIB1-Nb library using the McMahon method, 
whereby yeast was enriched for high affinity Nb-binders through 4 rounds of magnetic-
activated cell sorting (MACS) selection with successively lower concentration of labelled 
TRIB1 (McMahon et al., 2018). Enriched yeasts were plated as single colonies in a 96-well 
plate and stored at -80 °C. Tribble-1 nanobodies characterised in this study was recovered 
from that library. 
A sample of frozen yeast Nb library aliquots of selected TRIB1-Nb to be characterised in this 
study was taken and revived in 5 mL of Yglc4.5-Trp media in a 24 deep-well block overnight 
in an incubator at 30 °C and 230 rpm. Clonal expansion was checked by centrifugation at 
5000g and 4 °C, for 4 minutes using a 5810R centrifuge (Eppendorf). Following successful 
revival, yeast culture was centrifuged for Yglc4.5-Trp media replacement, to allow yeast 
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growth to stationary phase (~48 hours). An OD600 measurement was then taken to calculate 
yeast population density (OD600 of 1 ≈ 1.5 × 10
7 yeast cells).  
Initially, TRIB1-Nb clones revived (for this study) from the Mace Lab’s TRIB1-Nb library, 
were kept as frozen aliquots to passage for characterisation experiments. Yeast culture was 
centrifuged after reaching stationary phase, followed by removal of supernatant and 
resuspension of cells in 1 mL of Yglc4.5-Trp media supplemented with 10% DMSO; 450 uL 
aliquots (final density is ~ 1010 cells/mL) were stored at -80°C, using an isopropanol cell 
freezing chamber (Thermo Fisher Scientific cat# 5100-0001) to maintain cell integrity.  
2.2.3.2 Nanobody expression 
Once yeast cells were revived from the frozen TRIB1-Nb stock and incubated to reach 
stationary phase as mentioned in Section 2.2.3.1, the yeast cultures were centrifuged for the 
replacement of Yglc4.5-Trp media to pH 6 yeast media supplemented with glucose. This was 
followed by an overnight incubation at 30 °C and 230 rpm, to acclimate yeast cells to the 
more basic yeast media. For the expression of Nbs on the surface of yeast cells, the yeast 
cultures were centrifuged, and media replaced with pH6 yeast media supplemented with 
galactose. Yeast culture was then incubated for 24-48 hours, at 25 °C and 230 rpm. 
A reverse time course induction experiment was performed using Nb2.011, to determine Nb-
expression levels in yeast over time. Induction of yeast over a 48-hour period was performed 
with 3 induction replicates at 0 hours, 12 hours, and 24 hours. After 48 hours, cells were 
prepped for flow cytometry analysis by PE labelling as described in Section 2.2.4. 
Optimisation of the standard selection buffer (Table 2.1.5.1) was carried out to minimise non-
specific binding of TRIB proteins to yeast and Nbs. In this experiment, the standard selection 
buffer was supplemented with either: 
• 0.002% LMNG 
• 1%, 2% or 3% TWEEN® 20 (Sigma Life Science) 
• 2%, 4% or 6% Glycerol 
• 0.5% CHAPS (GLYCON Biochemicals GmbH) 
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These supplemented selection buffers were used to prepare uninduced and induced Nb-yeast 
clones for flow cytometry with 480 nM TRIB1-FITC as described in Section 2.2.4; An 
additional wash step with only standard selection buffer was done after removal of excess 
TRIB1-FITC. 
2.2.4 Characterisation of nanobody affinity and specificity 
For the characterisation of TRIB1-Nbs, yeast cell culture post Nb-induction, was prepped for 
flow cytometry analysis on the  Guava ExpressPlus (Guava® easyCyte™-5HT, Merck 
Millipore). For each Nb-yeast clone, an OD600 measurement of a 1 in 10 dilution sample was 
taken to calculate 1.5x cells needed for the experiments (1 x 106 cells for each sample, a total 
of 3 induction replicates) and for PE bulk labelling. An unlabelled control and a TRIB-FITC 
only control sample was also prepared for each yeast clone tested, with a PE only control 
gained from PE bulk labelling. Cells were centrifuged in 2 mL eppendorf tubes, at 5000g for 
3 min at 4 °C using 5424R centrifuge (Eppendorf). The yeast media was removed and 
replaced with 500 µL selection buffer, followed by another centrifuging step and removal of 
the supernatant. Cells were then added to 200 µL αHA-PE (1 in 10 dilution, 0.1 mg/ml), and 
incubated in foil, on a rotator for 1 hour at 4 °C. Following PE labelling of Nbs, yeast cells 
underwent 2x 500 µL selection buffer washes, before resuspension in 1.5 mL selection 
buffer. Resuspended yeast cells were dispensed as 90 µL samples in a 2 mL 96 well block. 
Cells were then incubated on a shaker at 500 rpm at room temperature for 60 minutes, with 
serial TRIB1-FITC/TRIB2-FITC concentrations (0-480 nM). Samples were then washed 2x 
with 500 µL selection buffer and resuspended with 1 mL of selection buffe. In a 96-well plate 
(flat-bottomed), 300 µL of samples were dispensed, ready for flow cytometry. 
2.2.4.1 Characterisation of TRIB1-Nb affinity 
For the affinity characterisation of TRIB1-Nb affinity against TRIB1, TRIB1 purified from E. 
coli was labelled with FITC (Pierce FITC Antibody Labelling Kit, Thermo Scientific) as 
stated by the manufacturer’s protocol, then snap frozen using liquid nitrogen and stored at -80 
°C. A serial dilution of TRIB1-FITC with selection buffer was performed to gain 
concentrations of; 480 nM, 240 nM, 120 nM, 60 nM, 30 nM, 15 nM, 7.5 nM, 0 nM. These 




2.2.4.2 Characterisation of TRIB1-Nb specificity  
For the specificity characterisation of TRIB1-Nb affinity over TRIB2, TRIB2 purified from 
E. coli was labelled with FITC (Pierce FITC Antibody Labelling Kit, Thermo Scientific) as 
stated by the manufacturer’s protocol, then snap frozen using liquid nitrogen and stored at -80 
°C.  
To characterise whether TRIB1-Nb had the ability to bind TRIB2, and consequently the 
potential to have less specificity against TRIB1, Nb-expressing yeast was incubated with 
TRIB2-FITC at 200 nM concentration as described in Section 2.2.4. Following, separate Nb-
expressing yeast samples was incubated with varying molar ratio concentrations of TRIB1-
FITC (200 nM) with unlabelled TRIB2 (200 nM) to gain concentrations of; 200 nM TRIB1-
FITC against 0 nM TRIB2 (1:0 molar ratio), 200 nM TRIB1-FITC against 200 nM TRIB2 
(1:1 molar ratio), 200 nM TRIB1-FITC against 1 µM TRIB2 (1:5 molar ratio), 200 nM 
TRIB1-FITC against 2 µM TRIB2 (1:10 molar ratio). These concentrations were used for 
TRIB1-Nb incubation with TRIB1-FITC as described in Section 2.2.4. 
2.2.5 Statistical analysis 
Analysis of flow cytometry data gained from Guava, was done using FlowJo 10.7.1. Yeast 
population was isolated from dead cells and debris, using the polygon gating tool. Control 
samples was then used to compensate FITC signal spillover into the PE channel. Following, a 
quadrant gating tool was applied to the unlabelled yeast clone controls, to separate the yeast 
population into Nb-expressors and non-Nb-expressors, and TRIB1/2 Nb-binders and non-
binders.  
For the analysis of the reverse time course induction performed on Nb2.011 yeast clones 
(n=3, Section 2.2.3.2), the bisector gating tool was set on the unlabelled control (PE 
histogram) in order to set an expression threshold for Nb-expressing yeast (Nb Pos). A mean 
fluorescence intensity (MFI) of the PE channel, as well as the population percentage of Nb-
Pos was then taken and exported for analysis on GraphPad Prism 8.4.3. A one-way ANOVA 
with Dunnett’s post hoc test was performed on the PE MFI data and Nb-Pos population data 
(%), to see how 48- and 36- hours of induction compared to 24 hours of induction (statistical 
significance of p < 0.05). 
For the analysis of the optimisation of standard selection buffer (n=3, Section 2.2.3.2) the 
bisector gating tool was set on the unlabelled control (FITC histogram) in order to set 
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threshold for non-specific binding of TRIB1-FITC to yeast. A FITC MFI of non-specific 
binding population was then taken and exported for analysis on GraphPad Prism 8.4.3. A 
one-way ANOVA with Dunnett’s post hoc test was performed on the FITC MFI data, to see 
whether the level of non-specific binding changed with modifications made to the selection 
buffer, when compared to the use of standard selection buffer for flow cytometry preparation 
(statistical significance of p < 0.05). 
For the characterisation analysis of TRIB1-Nb affinity (Section 2.2.4.1) and specificity 
(Section 2.2.4.2), a bisector gating tool was set on the unlabelled control (PE histogram) to 
identify the Nb-expressing yeast populations. From the Nb-Pos population, the mean 
fluorescence intensity of the compensated FITC channel was then taken and exported for 
analysis on GraphPad Prism 8.4.3. To characterise TRIB1-Nb affinity, a non-linear 
regression analysis was performed, where a one-site specific binding test was done to 
determine the dissociation constant (KD) of TRIB1-Nbs. To characterise the specificity of 
TRIB1-Nbs over TRIB2, a one-way ANOVA with Dunnett’s post hoc test was performed, 
where the TRIB1-FITC MFI at TRIB1 to TRIB2 molar ratio concentration of 1:0 was 
compared with every other TRIB1 to TRIB2 molar ratio concentrations (statistical 




The development of antibodies against proteins of interest for the use as a research tool takes 
time which may be streamlined by easy methods that can rapidly characterise multiple 
nanobodies in each experiment. In the passing years, as it is easy to express Nbs in bacteria 
and yeast due to its small size, Nbs surface display systems have been developed as a 
platform to accelerate the discovery of conformationally-selective Nbs against proteins of 
interest. 
To streamline the development of TRIB1 selective Nbs and further TRIB1 research, 
the McMahon yeast surface display platform was utilised alongside flow cytometry to 
characterise an approximate Nb affinity and specificity quickly; This was hypothesised to 
limit the putative TRIB1-Nbs to be taken into the next steps of the discovery pipeline from an 
existing Nb-library. Flow cytometry is a method that utilises the excitation of fluorophore-
labelled proteins by a laser, and detection of the resulting fluorescence of fluorophores to 
determine presence or interaction between proteins of interests. By labelling our protein of 
interest, TRIB1, with FITC in conjunction to using PE to label expressed Nbs by yeast 
clones, this would allow us to observe four different yeast populations from our flow 
cytometry analysis (Figure 3); Q1 – non-specific binding of TRIB1-FITC to yeast, Q2/Q3 – 
Nb-expressing yeast, Q2 – TRIB1-Nb binders, Q4 – unlabelled yeast.  
To characterise TRIB1-Nbs using the yeast surface display system and flow 
cytometry, we had to first make unlabelled and fluorophore-labelled TRIB1/2 proteins for 
TRIB1-Nb affinity and specificity characterisation. Next, a check of the induction time for 
optimal Nb-expression in our yeast clones. Non-specific binding of our target protein (TRIB1 
to yeast) also had to be accounted for as this would affect the MFI readings from flow 
cytometry that we used to calculate the Nb-affinities. Finally, TRIB1-Nbs were able to be 





Figure 3: Schematic of the yeast surface display system used to characterise TRIB1-Nbs using 
flow cytometry. Nbs are expressed on the surface of the yeast cell wall via an Aga1p-Aga2p 
mimicking covalent tether. The Nbs have an HA epitope that is labelled with PE. TRIB1 is labelled 
with FITC. Flow cytometry analysis of labelled yeast cells will generate a yeast population dot plot 
that can be separated into four different groups; Q1 – non-specific binding of TRIB1-FITC to yeast, 
Q2/Q3 – Nb-expressing yeast, Q2 – TRIB1-Nb binders, Q4 – unlabelled yeast. This figure was made 
using BioRender.  
3.1 TRIB1 and TRIB2 expression and purification. 
To investigate the affinities and specificities of putative TRIB-1 Nbs to its target using flow 
cytometry, TRIB1 and TRIB2 had to be expressed and purified for labelling with 
fluorophores. Previously, the Mace Lab cloned full-length TRIB1 (M627), and full-length 
TRIB2 (M924) constructs into expression vectors through Ligation Independent Cloning 
(LIC). Escherichia coli were transformed with either TRIB1 or TRIB2 constructs for the 
expression of proteins (Section 2.2.1, Figure 3.1.A). Proteins were expressed with a His6-tag 
which allowed for purification of proteins using His-select Ni2+-affinity resin (Section 
2.2.1.4, Figure 3.1.A – outlined by a purple box). SDS-PAGE was used to analyse samples; 
soluble, insoluble, flow-through, post-His6-tag-removal, and elution fractions from Ni
2+-
affinity purification (Section 2.2.2.1). A clear single band at ~33 kDa corresponding to the 
size of TRIB1 and TRIB2 proteins; This indicated success in the overexpression and 
purification of each TRIB construct from E. coli. The protein band of samples incubated with 
3C protease, being slightly below the Ni2+-affinity purification elution bands (Figure 3.1.B), 
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indicated the successful removal of the His6-tag from TRIB1; a similar observation was made 
for TRIB2 (Figure 3.1.D). A secondary purification of the eluted protein was performed post-
cleavage of the His6-tag, by using SEC. TRIB1 (~33.1 kDa) and TRIB2 (~33.3 kDa) proteins 
were eluted into B panel fractions which is at the expected size according to the S200 column 
(refer to Figure 3.1C and 3.1E, respectively). Purified TRIB1 and TRIB2 samples were then 
left unlabelled or labelled with FITC through primary amines (lysine side chains). FITC-
labelled TRIB1 and TRIB2 proteins were run through a desalting column, then analysed 
using a NanoDrop to check for successful FITC labelling. The yield of purified proteins (80 
uM TRIB1-FITC, 30 uM TRIB1, 100 uM TRIB2-FITC) in Section 3.1 allowed for the 




Figure 3.1: Expression and purification of TRIB1 and TRIB2 from E. coli BL21. A. Schematic 
made in BioRender of TRIB1/2 expressed in E. coli, which was followed by cell lysis and protein 
purification using Ni2+-affinity chromatography, outlined by the purple box. B. SDS-PAGE gel 
showing TRIB1 (31.1 kDa) expression (soluble and insoluble fractions, eluate pool, post-cleavage of 
His6-tag, post size exclusion pool fraction). C. Shows UV chromatography elution profile from a 
Superdex 200 (S200) SEC TRIB1 run, using post-cleavage TRIB1 proteins purified in A. D. SDS-
PAGE gel showing TRIB2 (33.3 kDa) expression (soluble and insoluble fractions, eluate pool, post-
cleavage of His6-tag, post size exclusion fractions). E. Shows UV chromatography elution profile 
from an S200 SEC TRIB2 run, using post-cleavage TRIB2 proteins purified in C. Red boxes indicate 
purified TRIB proteins. SEC: size exclusion chromatography. mAU: milli absorbance unit.  
 
 




3.2 Optimisation of yeast display system and flow cytometry methods. 
3.2.1 The optimal Nb-induction of yeast clones under galactose is 24 
hours. 
To utilise the yeast display system in conjunction to flow cytometry as a tool for initial 
characterisation screening of TRIB1-Nbs, the period for optimal Nb-expression in Nb-yeast 
clones was investigated through a reverse time course induction experiment (t=24 hours, t=36 
hours, t=48 hours; Section 2.2.3.2). For this investigation, only the Nb2.011 clone was used. 
A timeline of the experiment is shown in Figure 3.2.1.A, S. cerevesiae was induced to 
express Nbs under galactose. This was followed by labelling the HA epitope tag on Nbs 
expressed by yeast, using an αHA-PE antibody as described in Section 2.2.4. The flow 
cytometry data were analysed using FlowJo 10.7.1, with PE histograms generated out of the 
yeast population, then gated for positive Nb-expressers (Nb-Pos) using a bisector tool (Figure 
3.2.1.B and Appendix A.1) to gain a PE MFI and a percentage of Nb-Pos yeast population as 
described in Section 2.2.5. The raw data for PE MFI can be seen in Appendix A.2, whilst the 
data for the percentage population of Nb-Pos yeast can be seen in Appendix A.3. To see any 
significant changes within Nb expression in yeast, the percentage population of Nb-Pos yeast 
was normalised against unlabelled yeast controls – this minimised any background PE signal 
that was present. A one-way ANOVA with Dunnett’s post hoc test performed for sets of 
induction data: Induction times (t=36 and t=48) were compared against 24 hours. PE MFI 
was used as a measure of the level of Nb expressed in yeast clones. Overall, no statistical 
significance (p < 0.05) was found in the PE MFI across the time points (refer to Figure 
3.2.1.C and Appendix 1.4). However, there was a statistically significant drop found in the 
percentage population of Nb-Pos yeast between 24 hours and 48 hours of induction (p-value 
= 0.001, refer to Figure 3.2.1.D and Appendix 1.5). The level of Nb-PE fluorescence was 
relatively stable throughout the different induction times; however, the proportion of yeast 




Figure 3.2.1: Reverse time course induction of S. cerevesiae (yeast) Nb clones, under galactose-
supplement pH 6 yeast media (n=3). Nbs were labelled with αHA-PE before flow cytometry runs 
using Guava ExpressPlus. Column graphs with mean and standard deviation (SD) were generated 
using GraphPad Prism 8.4.3, with a one-way ANOVA with Dunnett post-hoc test performed to find 
significant difference *(p <0.05), ** (p < 0.005). A. A schematic of the reverse time course induction 
experiment performed for t=24 hours, t=36 hours and t=48 hours of induction. B. An example of 
bisector gating in FlowJo 10.7.1, for Nb-Pos population using an unlabelled yeast control, which was 
then applied to other samples for analysis. C. No significant difference is seen in overall Nb 
expression (PE MFI) on the surface of yeast between 24-48 hours of galactose induction. D. 
Population of Nb-expressing yeast decreased significantly between 24 and 48 hours of galactose 
induction. Nb: Nanobody. Nbs: Nanobodies. MFI: Mean fluorescence intensity.  
3.2.2 Standard selection buffer is optimal for flow cytometry analysis. 
To try and minimise potential affinity and specificity overestimation of TRIB1-Nbs 
investigated in this study, non-specific binding of labelled TRIB proteins to yeast had to be 
minimised. One of the limitations to using flow cytometry to characterise Nb affinity and 
specificity using a yeast surface display system is that it is highly dependent on the signal 
intensity of the fluorophores used to label the Nbs of interest and the protein of interest it 
targets. We must ensure that the fluorophores used, as an indicator of Nb binding to our target 
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protein, fluoresce at a level that generates a meaningful observation. As we use the FITC MFI 
to calculate the affinity of the Nbs, any changes to the MFI observed that is not due to true 
binding of our TRIB1-Nbs to TRIB1-FITC will skew our affinity calculations. 
When yeast populations of induced and uninduced Nb-yeast clones (Nb5.018 – negative 
control, Nb2.012 – positive control, Nb2.038, Nb2.049, Nb2.066)  was observed using flow 
cytometry, it was shown that TRIB1-FITC non-specifically bound to the surface of yeast (Q1 
population, Appendix B.1). Consequently, uninduced yeast clones (Nb5.018 – negative 
control, Nb2.012 – positive control), were prepared for flow cytometry using the standard 
selection buffer and standard selection buffer supplemented by varying concentrations of 
detergents (TWEEN-20, CHAPS, and LMNG) and glycerol as described in Section 2.2.3.2, to 
see whether non-specific binding could be lowered. Flow cytometry data on Guava 
ExpressPlus (Appendix B.2-3) was processed using FlowJo, where a quadrant gate was 
applied to show the different yeast populations. A bisector gate was applied to the FITC 
histogram was used to determine the unlabelled yeast population (showing specific binding) 
against the yeast population non-specifically binding to TRIB1-FITC.  A one-way ANOVA 
with Dunnett’s post hoc test was performed on the TRIB1-FITC MFI of non-specific TRIB1 
binding to yeast (Appendix B.4), and on the percentage of yeast population non-specifically 
binding to yeast (Appendix B.5). Column graphs were generated using GraphPad Prism 8.4.3, 
with mean and SD shown (Nb 5.018 graphs see Figure 3.2.2.A-B, Nb 2.011 graphs see 
Figure 3.2.2.C-D). Results showed, that when using modified standard selection buffer 
compared to standard selection buffer, no significant reduction in the level (Appendix B.6) or 
percentage of yeast population (Appendix B.7) of non-specific binding of TRIB1-FITC to 
yeast was seen (p < 0.05). Similarly, any significant reduction in non-specific binding, for a 
supplemented selection buffer, that was not present across both Nb clones tested (Nb5.018 
and Nb2.011) was reconsidered as being not significant overall. Consequently, it was 
determined that the standard selection buffer was already optimal for flow cytometry analysis 




Figure 3.2.2: Optimisation of selection buffer for flow cytometry analysis – standard selection 
buffer is optimal. Uninduced Nb yeast clones (Nb5.018 and Nb2.011) was incubated with 480 nM of 
TRIB1-FITC, then analysed using Guava Express Plus. Flow cytometry data was gathered and 
processed using FlowJo 10.4.1. Column graphs were generated using GraphPad Prism 8.4.3, with 
mean and SD (n=3) showed with statistical significance shown * (p < 0.05). A. No significant 
difference was observed in Nb5.018 yeast population of yeast non-specifically binding TRIB1-FITC 
when standard selection buffer was modified by the addition of reagents. B. A significant difference 
in the level (MFI) of non-specific binding of yeast to TRIB1-FITC was seen in Nb5.018 yeast when 
standard selection buffer was supplemented 6% glycerol. However, this result was not translated over 
to Nb2.012 in D. C. No significant difference was observed in Nb2.011 yeast population of yeast non-
specifically binding TRIB1-FITC when standard selection buffer was modified by the addition of 
reagents. D. No significant difference in the level (MFI) of non-specific binding of yeast to TRIB1-
FITC was seen in Nb2.011 yeast when standard selection buffer was supplemented with reagents. 
Nb5.018: Nanobody yeast clone against an unrelated protein (negative control). Nb2.011: Nanobody 
yeast clone that is known to bind TRIB1 (positive control). MFI: Mean fluorescence intensity. 
3.2.3 Compensation of FITC-PE spillover and gating of yeast 
populations. 
It is known that FITC (green) fluorescence bleeds over into the PE (yellow) channel due to an 
overlap in their emission spectrum. Therefore, before any analysis could be done using PE 
and FITC fluorescence on flow cytometry data, FITC signalling must be compensated. 
Compensation of FITC to PE spillover was done using the compensation matrix in FlowJo. A 
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bisector gate was used to determine the threshold for FITC and PE signalling (Figure 
3.2.3.1.A); the bisector gate was chosen as this would remove the likelihood of accounting 
any yeast cells into both negative and positive groups. This was followed by adjustment of 
the fluorescent readouts so that the FITC signal no longer resulted in a false-positive PE 
signal (Figure 3.2.3.1.B). Compensation of the FITC-PE spillover was recognised when the 
FITC only control of samples, no longer showed cells in Q2 and Q3 (Figure 3.2.3.1.C). Refer 
to Appendix C for example of compensation applied to all characterisation experiments in this 
study. 
 
Figure 3.2.3.1: Compensation of FITC-PE fluorescence spillover using FlowJo and Nb2.011 as 
an example. A. An unlabelled control was used to determine the gate for FITC-negative and FITC-
positive outcomes in the green fluorescence channel (GRN-HLog) using the bisector tool. FITC-
positive population from the FITC-only control sample for Nb2.011 was then viewed for PE 
fluorescence in the yellow channel as a histogram to set a PE-negative gate using the bisector tool 
which was then transferred to Nb2.011 PE-only control. B. The compensation tool in FlowJo was then 
utilised to correct for FITC signalling bleeding into the PE channel, with the matrix edited manually 
to ensure more accurate compensation was applied to sample populations. C. With compensation 
applied, FITC-only control samples are expected to no longer show positive signalling in the PE 




Once compensation of FITC-PE is done, flow cytometry data gained from characterisation 
experiments may be analysed using FlowJo (Figure 3.2.3.2). First, a polygon gating tool was 
used to select for the yeast population, removing readouts from debris and potential dead 
cells. The dot plot of side scatter (cell granularity) vs forward scatter (cell size) is then 
converted into a dot plot of PE (Nb) fluorescence vs FITC (TRIB1) fluorescence; a quadrant 
gate is used on negative control samples to be able to differentiate different yeast populations 
as shown in Figure 3. The dot plot is then converted into a PE histogram, where an 
unlabelled control is separated into non-Nb expressers (Nb Neg) and Nb Pos populations. The 
FITC MFI used to calculate TRIB1-Nb affinities is gained from the Nb Pos population. 
 
Figure 3.2.3.2: Example of gating the yeast population to characterise TRIB1-Nbs. Nb2.011 
samples were used in this example. FlowJo 10.7.1 was used to first gate the yeast population from 
dead cells and debris. The yeast population was then graphed onto a dot plot of PE vs FITC 
fluorescence, where a quadrant gate was applied to show the different yeast populations. This was 
then converted into a PE histogram to gain FITC MFI of Nb Pos population: An unlabelled control 
was used to set a PE threshold using the bisector gating tool - this classified yeast cells as either Nb 
expressers (Nb Pos) or non-Nb expressers (Nb Neg). Red arrows indicate what application of the 
gates set with an unlabelled control looks like on labelled samples. 
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3.3 Affinity characterisation of TRIB1-Nbs. 
Eight TRIB1-Nbs, previously screened as putative TRIB1 binders were studied based on 
sequence enrichment form the naïve library (Table 2.1.2.2). Yeast cells were cultured, 
induced, and prepared for flow cytometry as described in Section 2.2.3. The affinity of 
TRIB1-Nbs was measured by the FITC MFI of the Nb-Pos yeast population (Q1 and Q2, 
Figure 3,  Appendix D-H). The raw data of MFI gathered using FlowJo 10.7.1 (Appendix I) 
was analysed using non-linear regression, one-site specific binding test, where a binding 
curve was generated for each profiled Nb (Figure 3.3). This calculated an equilibrium 
dissociation constant (KD), where the value of the KD is inversely proportional to the strength 
of the binding affinity that a ligand has to its target.  
The initial affinity characterisation of TRIB1-Nbs was performed using eight titrations of 
TRIB1-FITC concentrations (0-480 nM). The maximum TRIB1-FITC concentration of 480 
nM was chosen, as the non-specific binding of TRIB1-FITC to yeast increased by a large 
amount past this concentration, and the desired TRIB1-Nbs to use in future studies are those 
with low nM KD. Results showed that most of the Nbs did not have a very high affinity to 
TRIB1 at the nanomolar range (Table 3.3.1). Three TRIB1-Nbs showed good binding against 
TRIB1 (Nb2.038, Nb2.049, and Nb2.066 – highlighted in Table 3.3.1) and was further tested 
for its affinity using 12 TRIB1-FITC concentrations (0-480 nM – 1 nM, 2 nM, 4 nM and 10 
nM concentrations replaced the 7.5 nM titration) (Appendix I.15). By starting with lower 
concentrations of TRIB1-FITC, the non-linear regression curve able to be generated will be a 
more accurate representation of the binding kinetics between TRIB1-Nb with its target 
TRIB1. These Nbs were also tested again, within the same experiment, so that a more 
accurate KD could be calculated using normalised data; where the FITC MFI of Nb5.018 is 
subtracted from the FITC MFI generated by TRIB1-Nb binding TRIB1-FITC to account for 
non-specific binding. However, the second trial of affinity characterisation using more 
TRIB1 dilutions showed that Nb2.038 (Figure 3.3.2.A), Nb2.049 (Figure 3.3.2.B) and 
Nb2.066 (Figure 3.3.2.C) did not have a higher affinity to TRIB1 when compared to the 
positive control, Nb2.011. 
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Figure 3.3.1: Binding curves of TRIB1-Nbs against 8 TRIB1-FITC titrations (0-480 nM). An 
affinity characterisation study using the yeast display system in conjunction with flow cytometry was 
performed on TRIB1-Nbs with 8 titrations of TRIB1-FITC. Each TRIB1-Nb binding study was 
carried out with the negative control, Nb5.018. Non-linear regression, one-site specific binding test 
(n=3) was done using GraphPad Prism 8.4.3. Each graph shows the non-linear regression curve, with 
each replicate shown apart from data at 0 nM of TRIB1-FITC due to the nature of a log scale. A. 
Nb.2.011 (positive control), B. Nb2.012, C. Nb2.029, D. Nb2.031, E. Nb2.038, F. Nb2.049, G. 
Nb2.060, H. Nb2.066, and I. Nb2.074. TRIB1 binding curve in Nb2.038 (E), Nb2.049 (F), and 
Nb2.066 (G) nice sigmoidal trend expected of a good binder; A second affinity characterisation trial 




Table 3.3.1: Summary table of TRIB1-Nb affinity to TRIB1.  
 
 
Figure 3.3.2: Binding curves of TRIB1-Nbs against 12 TRIB1-FITC titrations (0-480 nM). An 
affinity characterisation study using the yeast display system in conjunction with flow cytometry was 
performed on TRIB1-Nbs. Each TRIB1-Nb binding study was carried out with the negative control, 
Nb5.018. Non-linear regression, one-site specific binding test (n=3) was done on raw and normalised 
data using GraphPad Prism 8.4.3. FITC MFI of Nb5.018 binding TRIB1-FITC was subtracted from 
FITC MFI of TRIB1-Nbs tested, to account for non-specific binding. Each graph shows the non-linear 
regression curve, with each replicate shown apart from data at 0 nM of TRIB1-FITC due to the nature 
of a log scale. A. Nb2.038, B. Nb2.049, C. Nb2.066.  
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3.4 Specificity characterisation of TRIB1-Nbs over TRIB2. 
Nanobodies are known to be highly conformationally selective, with minimal sequences. The 
ability of Nbs to have such high specificity against its target ligand makes it a promising tool 
to study specific TRIB homologue signalling pathways in vitro, as TRIB homologues show a 
high degree of homology. To investigate whether the TRIB1-Nbs studied were specific for 
TRIB1 over another TRIB homologue, TRIB2 (which shares ~70% sequence identity), a 
competition assay was done as described in Section 2.2.4.2. Due to time constraints, this 
specificity characterisation was limited to Nb2.038 and Nb2.066, alongside the negative and 
positive Nb controls (n=3). This assay allowed us to observe whether an unlabelled TRIB2 
would be able to outcompete TRIB1-FITC binding to the TRIB1-Nbs: A decrease in FITC 
MFI then indicates a reduction in TRIB1-Nb binding to labelled TRIB1 and subsequently 
reduced specificity of TRIB1-Nb for TRIB1. Flow cytometry data was analysed using 
FlowJo 10.7.1 (Appendix K.1), where the raw data (FITC MFI, Appendix K.3) was analysed 
using a one-way ANOVA test with Dunnett’s post hoc, to show whether there were any 
significant TRIB1-FITC MFI changes of samples with 200 nM TRIB1-FITC and 0 nM 
TRIB2 when compared to samples with fixed TRIB1-FITC concentration (200 nM) and 
increasing molar ratio concentrations of TRIB2. A column graph was generated to show the 
results of the competition assay, where each replicate was shown with the mean and standard 
deviation (SD) (Figure 3.4.1.A). Results showed that there were no significant changes (p 
<0.05) seen in the intensity of FITC signalling (Appendix K.4).  
To see whether the TRIB1-Nbs tested and the positive control Nb could have bound to 
TRIB2 due to the sequence homology, a shallow binding affinity test was executed where 
induced yeast clones were incubated with 200 nM of TRIB2-FITC. The FITC MFI of TRIB2 
binding to TRIB1-Nbs when compared to the negative control, Nb5.018 (Figure 3.4.1.B), 
showed that Nb2.011, Nb2.038 and Nb2.066 did bind TRIB2 (but this needs to be further 
investigated as it could have been caused by non-specific binding seen with TRIB1). Overall, 
the specificity assays carried out for the three TRIB1 Nbs suggests that the two TRIB1-Nbs 
tested plus the positive control, Nb2.011, were specific for TRIB1 over TRIB2 despite the 




Figure 3.4.1: Competition assay to determine the specificity of 3 TRIB1-Nbs over TRIB2, which 
shares ~70% sequence identity. The competition assay (n=3) was done using a yeast display system, 
where Nbs expressed on the surface of the yeast cell wall was incubated with a set concentration of 
TRIB1-FITC with a fold increased molar concentration of unlabelled TRIB2: e.g. 1:5 of TRIB1: 
TRIB2 means 200 nM of TRIB1 with 2 µM of TRIB2. A. Shows column graph with mean, standard 
deviation (SD) and each replicate data shown. No statistical significance was seen between 1:0 molar 
concentrations of TRIB1 to TRIB2 and TRIB1 with 1x/5x/1x TRIB2 concentration. Nb2.011, 
Nb2.038 and Nb2.066 are specific for TRIB1 over TRIB2. B. Shows graph of FITC MFI of 200 nM 
TRIB2-FITC binding to TRIB1-Nb. Compared to negative control binder, Nb5.018, Nb2.011, 




TRIB studies have made observations where it has contradictory roles in cancer pathogenesis. 
With its role as an adaptor protein, TRIB proteins associate with many substrates to regulate 
signalling pathways such as the C/EBPα, MEK and Akt pathways related to cell 
differentiation, growth, and survival. TRIB proteins, therefore, exist in a heterogeneous 
fashion, where its multiple transient complexes allow it to modulate varying signalling 
pathways in either inhibitory or stimulatory manner. Studying one aspect of TRIB signalling 
and how it consequently results in disease when dysregulated, is hard without an efficient 
research tool that can stabilise its selective conformations. TRIB-specific Nbs may potentiate 
further human TRIB studies and reduce the gap in knowledge for understanding the 
contradictory roles of TRIB as a tumour suppressor and an oncogenic factor in diseased 
states. This study used a yeast display system with flow cytometry and aimed to characterise 
the affinity and specificity of TRIB1-Nbs. The results of the TRIB1-Nb characterisation 
study will be discussed, as well as whether the use of the yeast display system with flow 
cytometry is efficient for the initial characterisation screen of selected TRIB-Nbs from a Nb-
library, for the initial discovery pipeline. 
4.1 Optimisation of yeast display system and flow cytometry methods. 
4.1.1 The optimal Nb-induction of yeast clones under galactose is 24 
hours. 
In order to investigate the affinity and specificity of TRIB1-Nbs using the yeast display 
system created by the McMahon Group, Nbs had to be adequately expressed on the surface of 
the yeast clones to gain reasonable data for analysis. Previously, in the development of the 
McMahon Nb-yeast display system, an N-terminal engineered mating factor α preprotein was 
added to enhance the yeast expression of synthetic Nbs (McMahon et al., 2018): They 
observed that Nb expression levels were optimal between 48-72 hours of induction under 
galactose. However, a similar yeast display system created by the Uchański group saw that an 
overnight induction under galactose was sufficient to generate ~60% of the total yeast 
population to display their Nbs (Uchański et al., 2019). Subsequently, we first wanted to 
observe whether our TRIB1-Nb yeast clones were able to generate the same level of 
expression and at what induction time was the most optimal to execute for this study through 
the execution of reverse time course induction.  
Our findings (Section 3.2.1) showed that 24 hours was the optimal induction time for our 
yeast clones, with roughly 30% of the total yeast population expressing Nbs (Figure 3.2.1.D). 
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The expression of Nbs within the total population of Nb2.011 clones, being roughly half of 
what we expected based on previous literature (Uchański et al., 2019), may be explained by 
any residual glucose present strongly repressing the expression of GAL1-induced genes until 
a later time at which glucose levels in cells are low enough to release repression (Weinhandl 
et al., 2014). It may also be explained by our PE labelling showing depletion, as indicated by 
a spike in amplitude at high PE fluorescence (Figure 3.2.1.B): This suggests an 
underestimation of the level of Nb expressed by our yeast population. To overcome this, a 
more concentrated αHA-PE labelling of our antibody could have been done than just a 1 in 
10 dilution (Section 2.2.4). However, this was not executed as the concentration of αHA-PE 
was already double than initially planned and depletion of our PE label was still observed. 
Unlike the McMahon group who observed better Nb-expression at 48 hours of induction, we 
observed that with increasing induction time, the total population of yeast expressing Nbs 
decreased from ~35% at 24 hours of induction, to ~10% at 48 hours of induction, but the 
level of PE MFI (an indicator of overall Nb expression) did not significantly 
increase/decrease over time (Figure 3.2.1.C). Growth of yeast culture under galactose, 
leading to an increase of total yeast population that decreased the ratio of Nb-Pos yeast, 
cannot explain this observation. Yeast growth occurs at a minimum in the condition of 
galactose with pH 6 yeast media that was used for induction. Galactose metabolism in yeast 
requires a high level of energy diverted into producing GAL enzymes (Stockwell et al., 2015) 
and, S. cerevesiae is an acidophilic organism that better grows in lower pH media (Peña et 
al., 2015) that does not require the diversion of energy into maintaining optimal pH 
environment for enzymes and transport proteins associated with growth (Narendranath and 
Power, 2005). Since our Nb expression was controlled under the GAL1 promoter, reducing 
levels of galactose in our culture over 48 hours could have been the reason why we observed 
a very significant decrease in the number of Nb2.011 yeast cells expressing Nbs (p = 0.001) 
without seeing a change to the level of Nb expression in individual yeast cells, when 
compared to 24 hours of induction. Expression of GAL1 genes requires sufficient 
displacement of Gal80 proteins that represses the DNA-binding target protein of the GAL1 
promoter, Gal4 (Johnston, 1987; Weinhandl et al., 2014). Without adequate removal of 
Gal80 repression of Gal4 by the inducer (Gal3p activated by galactose) (Stockwell et al., 
2015), there would not have been continued, high induction of Nb expression in the total 
yeast population. This may be in conjunction to a build-up of waste metabolites and 
starvation over a 48-hour period, which may have resulted in yeast cells reverting to a 
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survival mode which restricted our recombinant protein expression (Petti et al., 2011): 
Starvation leads to a metabolic change in yeast where genes related to translation is repressed 
and degradation of non-essential proteins increases.  
 4.1.2 Optimisation of selection buffer. 
The characterisation of Nbs with the use of a yeast display system in conjunction with flow 
cytometry is very much dependent on the level of fluorescence seen in the fluorophores used 
and how it affects the resulting MFI which is used for analysis. Any non-specific binding of 
our TRIB1-Nbs to uninduced Nb-yeast clones could have potentially led to an overestimation 
of affinity/specificity of our tested TRIB1-Nbs with induced yeast clones and Nb labelling. 
We had observed consistent non-specific binding of TRIB1-FITC to uninduced and induced 
Nb-yeast clones (Appendix B.1). Hence, we attempted to optimise our standard selection 
buffer by addition of reagents (LMNG, CHAPS, TWEEN-20, and glycerol) that are typically 
used to minimise non-specific binding of proteins. The detergents used to supplement our 
selection buffer were chosen for the following reason; the zwitterionic CHAPS, non-ionic 
TWEEN-20 (Johnson, 2013), and integral membrane protein stabiliser, LMNG (used to 
enrich Nb5.018) (Chae et al., 2010), are reported to not compromise the integrity of proteins 
of interest and their protein-protein interactions studied using flow cytometry. Due to the 
presence of a phenyl ring in TWEEN-20, it can absorb UV light at  ~280 nm (Johnson, 2013), 
and although this would not have any effects on our flow cytometry reading due to the 
excitation/emission wavelengths of the fluorophores used in this study (Table 2.1.6.1), 
additional wash steps with standard selection buffer executed (Section 2.2.3.2) to remove the 
detergent as a precaution. The addition of glycerol to standard selection buffer was also 
tested, to see whether increased suspension of yeast cells and TRIB1/2 proteins used in this 
study, would minimise the contact between TRIB1/2 proteins and the unrelated yeast surface: 
Previously, the Mace lab had observed that recombinant TRIB proteins behaved better in 
selection buffer containing glycerol. 
Our results (Section 3.2.2) showed that in both our positive (Nb2.011) and negative 
(Nb5.018) control Nb-yeast clones, our modification of selection buffer had no significant 
effects in reducing the observed non-specific binding. Although the addition of 0.5% CHAPS 
was seen to significantly change non-specific binding (p < 0.0001), it was not the desired 
reduction but an increase that was observed. This may have resulted from the high 
concentration used, causing its aggregation and affecting the binding of TRIB1-FITC non-
40 
 
specifically to yeast, and/or it also binding to hydrophobic regions of yeast surface proteins 
and being detected during flow cytometry analysis. Similarly, to CHAPS, any significant 
changes observed using modified selection buffer, which increased non-specific binding was 
ignored (Appendix B.6-7). Although glycerol at 6% did result in a significant decrease of 
TRIB1-FITC non-specifically binding to yeast Nb5.018 (p = 0.0143, Appendix B.7), a similar 
observation was not seen in yeast Nb2.011. Consequently, the use of selection buffer with 6% 
glycerol was not implemented, as this data implied that the level of non-specific binding 
varies across yeast clones and experiments: This indicated that modification to the standard 
selection buffer would have little to no significant effects in minimising non-specific binding. 
Instead, non-specific binding could be accounted for, post-flow cytometry analysis, by 
subtracting the mean MFI of Nb5.018 (negative binding control) from the MFI data of tested 
TRIB1-Nbs (Uchański et al., 2019): This, however, was dependent on there being similar 
induction seen between the negative control yeast clone and tested yeast clones, as well as 
consistent non-specific binding across the yeast clones.   
4.2 Characterisation of TRIB1-Nbs. 
4.2.1 TRIB1-Nb affinity found suggested further library screening. 
As previously mentioned, the yeast display system has been characterised as a tool for the 
rapid discovery of Nbs to POIs. TRIB1-Nbs were initially pooled from an existing Nb library 
by rounds of MACs selection against decreasing concentration of TRIB1 proteins into the 
nanomolar range. Positive TRIB1 binding population were enriched, followed by next 
generation sequencing of individual clones of recombinant yeast. The top 8 TRIB1-Nbs that 
were enriched, were chosen to be tested in this research project. By using the initial KD 
estimates calculated from flow cytometry, it is possible to further identify the best binding 
candidates from the TRIB1-Nb library, to be taken into later stages of development. We 
implemented the yeast display system in conjunction with flow cytometry, to observe 
whether this method worked to streamline the affinity characterisation of TRIB1-Nbs in this 
study - potentially reducing the time needed for the initial Nb discovery in the development 
pipeline. 
First, the affinity characterisation result for Nb2.011 was compared to the isothermal titration 
calorimetry (ITC) assay result of free Nb2.011 co-eluted with TRIB1 (another method for 
determining protein-protein interactions). Our results showed that Nb2.011 had ~315 nM 
(Table 3.3.1) affinity to TRIB1, which was comparable to the ITC result, which was 366 nM 
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(Mace Lab, unpublished data). This showed proof that affinity characterisation using the 
yeast display system and flow cytometry (a more rapid approach than ITC), could garner an 
affinity approximation that is close to the actual affinity value. The yeast display system was 
validated as a tool to characterise the 8 chosen TRIB1-Nbs. Although we did not see 
saturation in the binding between TRIB1-Nbs and TRIB1 proteins (Figure 3.3.2), as an initial 
affinity screening for high affinity binders, it was deemed unnecessary to increase the range 
of TRIB1 concentrations; a non-saturated binding curve with a highest TRIB1 concentration 
of 480 nM, would suggest that the TRIB1-Nb KD is higher than the calculated value (low 
affinity), which is undesirable. 
Second, initial affinity screening of TRIB1-Nbs using 8 titrations of TRIB1-FITC 
concentrations (nM; 0, 7.5, 15, 30, 60, 120, 240, 480), showed three potential high-affinity 
candidates (Nb2.038, Nb2.049, and Nb2.066) with affinities that were calculated to be higher 
than the positive control Nb2.011 (Table 3.3.1). These Nbs were then characterised using 
ITC, but results showed that, although they did show binding to TRIB1 proteins, it was at a 
lower affinity than the flow cytometry data suggested (Mace Lab, unpublished data). This led 
to a second affinity screening of the 3 candidates (Nb2.038, Nb2.049, and Nb2.066) using 12 
titrations of TRIB1-FITC concentrations (nM: 0, 1, 2, 4, 8, 10, 15, 30, 60, 120, 240, 480). 
The results of the second affinity screening showed that the three (initially) promising Nbs 
were not actually better TRIB1 binders when compared to Nb2.011 (Figure 3.3.2). This may 
be due to the use of lower TRIB1-FITC titrations which would make the fit of the overall 
binding curve and calculated KD closer to the actual value. Also, with the second affinity 
screening, we were able to subtract the mean FITC MFI from the Nb5.018 data, to account 
for the non-specific binding of TRIB1 to yeast cells. In the first affinity screening,  the mean 
FITC MFI values for Nb5.018 (negative controls) were too high to subtract with, when 
compared to the FITC MFI of TRIB1-Nbs tested; generating negative values that could not 
be used to calculate a KD. Hence, the second affinity screening may have successfully 
accounted for the non-specific binding that may have resulted in the overestimation of 
TRIB1-affinity seen in the first affinity screening. 
Our TRIB1-Nb affinity characterisation study showed that none of the 8 Nbs tested from the 
TRIB1-Nb library were better TRIB1 binders than Nb2.011. The TRIB1-Nb library used in 
this study was from one of the initial implementations of the McMahon method by the Mace 
lab. This would have limited the ability to reduce the initial Nb library down to potential 
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high-affinity TRIB1-Nbs. In future, starting at a lower concentration than 480 nM of TRIB1, 
(where we observed a higher degree of non-selective binding) may be beneficial as it would 
select for TRIB1-Nbs without confounding from non-selective binding. Also, stringent 
selection using much lower concentrations of TRIB1 would have selected for better TRIB1-
binders to test. In literature, selection of Nbs from a naïve library using picomolar 
concentrations of their proteins of interests, yielded better affinity screening results using the 
yeast display system and flow cytometry (McMahon et al., 2018; Uchański et al., 2019). 
Since the initial use of the McMahon method, the execution should be better known, and 
another screening of TRIB1-Nbs from the McMahon Nb library is suggested in future for the 
discovery of better TRIB1-Nbs. 
4.2.2 TRIB1-Nb specificity over TRIB2 attributed to inherent Nb 
conformation. 
Although none of the tested TRIB1-Nbs in this study showed higher affinities to TRIB1 when 
compared to Nb2.011, the TRIB1-Nbs tested for TRIB1 specificity did show preferential 
binding to TRIB1 over the TRIB2 homologue (Section 3.4). The TRIB1-Nbs used in this 
study, despite only comprising of ~100 amino acid sequence and showing differences within 
only small sequence portions of their complementary determining region (CDR) loops 
(Figure 4.2.2.1), managed to show variable TRIB1 affinity but showed similar specificity 
profiles to TRIB1 over TRIB2 (Figure 3.4.1.A). The targeted sites of the TRIB1-Nbs studied 
in this project were, however, unknown. The specificity profile seen, may be explained by the 
inherent Nb characteristics, which allows it to have a high degree of specificity despite its 
relatively short sequence, and hence a short paratope. In future it may be of interest, to study 
whether small sequence variance in TRIB1-Nbs’ CDR loops, result in it targeting different 
sites along the TRIB1 protein and if they were to target similar sites, whether their 
affinities/specificities are similar or different.  
Point mutations in camelid Vhh’s occur more frequently within or in proximation of the 
paratope regions that have significance in determining Nb structural loops/conformation 
(Kunik et al., 2012; Nguyen et al., 2000; Sela-Culang et al., 2013). Consequently, unlike the 
high sequence variance in framework regions or CDR loops seen in conventional antibodies, 
it is theorised that Nb specificity to bind antigens is dependent on the increased structural 
diversity in their CDR loops (in particular, the lengthened CDR3) in the Vhh (Mitchell and 
Colwell, 2018; Nguyen et al., 2000). The absence of the light chain may have resulted in the 
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evolved nature of VHH in nanobodies to be specific for novel paratopes (Nguyen et al., 
2000). Little changes to the Nb sequence, can result in a different conformational state that is 
able to exploit different epitopes compared to conventional antibodies which require higher 
variability to gain the same result (Mitchell and Colwell, 2018).  
Figure 4.2.2.1: The construction of synthetic Nbs using the McMahon method. This schematic 
was obtained from (McMahon et al., 2018). The complementary determining (CDR) loops that have 
been studied to determine the affinity and specificity of Nbs to its target, were modified to result in a 
range of Nbs with different characteristics. Dotted lines show the CDR amino acid residues that may 
differ across the Nbs used in this study. The Nb framework regions in grey, were kept the same across 
all Nbs used in this study. Nbs: Nanobodies. 
4.3 Future Directions 
Overall, this study had shown that the yeast display system previously developed by the 
McMahon group to rapidly discover GPCR Nbs, could be implemented for the rapid 
discovery of TRIB1-Nbs (also suggested for TRIB2 and TRIB3). Compensation is necessary 
for flow cytometry when fluorophores have overlapping emission spectrums. We had 
successfully overcome compensation of our FITC and PE channels (Section 3.2.3); however, 
it is noted that our FITC signal at our highest concentration of TRIB1-FITC (480 nm) was not 
as high as we had expected it to be and therefore, compensation may not have been executed 
evenly between experiments. To overcome this compensation issue, future studies for the 
characterisation of TRIB-specific Nbs may be improved through the use of fluorescent beads 
for more accurate flow cytometry compensation of FITC spill-over into the PE channel, or 
through the use of a different labelling methodology that utilises fluorophores without 
overlapping spectrums. Also, another labelling system should be used for the Nbs expressed 
on the surface of yeast cells, so that no depletion of our PE labelling is observed like within 
this study, (as mentioned in Section 4.1.1). One such labelling that could be implemented for 
visualising Nb expression would be CoA-547 which was shown to be effective by the 
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Uchański group (Uchański et al., 2019). Furthermore, future specificity trials using the yeast 
display system could be expanded by using a positive TRIB2-Nb control (tested against 
TRIB1) for comparison of TRIB1-Nbs, as well as using positive control of unlabelled TRIB1 
against labelled TRIB2 proteins: If TRIB1-Nbs were specific against TRIB1 proteins, you 
would expect near 100% blocking of TRIB2 binding to TRIB1-Nbs.  
By implementing the changes mentioned above, it may be possible to develop TRIB-specific 
Nbs with high affinities, for the use of future in vitro study. Although Nbs are highly soluble 
in aqueous solutions, it cannot spontaneously pass through the plasma membrane to reach its 
target in vitro (Desmyter et al., 2015; Hassanzadeh-Ghassabeh et al., 2013). However, 
modifications like the addition of cyclic arginine-rich peptides can facilitate cellular 
internalisation of Nbs for in vitro research (Herce et al., 2017). In the far future, when high-
affinity TRIB-Nbs has been developed and verified, Nb modification could mean facilitation 
of complex TRIB-signalling studies for diseases and the development of new and specific 
therapeutics associated with it. 
Being able to study the inhibition/destabilisation/degradation of TRIB proteins can give a 
platform for the development of therapeutics that target the same sites as TRIB specific Nbs 
to induce the same beneficial response. Nanobodies can be utilised to control protein 
expression through degradative means for studies and discovery of new therapeutics. Genetic 
protein inactivation occurs over a period that is ineffective for therapeutic purposes. 
Therefore, the use of small protein inhibitors is more common in developing new therapeutics 
where minimising protein expression is necessary to mitigate the development of a disease. 
However, small protein inhibitors have low accuracy to protein targets which lead to off-
target effects. The deGradFP technology consists of an F box protein called Slmb (derived 
from Drosophila melanogaster) fused to a Nb fragment (VhhGFP4), which can elicit 
significant target protein degradation through cullin E3 ligase recruitment, see Figure 4.3.1, 
(Caussinus et al., 2012; Yamaguchi et al., 2019): Protein degradation through this method is 




Figure 4.3.1: Nb-protein degradation system. deGradFP schematic adapted from (Yamaguchi et al., 
2019) showing VhhGFP4 Nb fragment (dark blue) bound to F-box protein (burnt orange) which can 
recruit the cullin-RING ubiquitin (Ub) ligase (simply represented by E3 and E2 ligases in light blue), 
that facilitates K48 ubiquitination of GFP-POI (protein of interest) in drosophila flies. Figure made 
using BioRender. 
Transgenic drosophila flies, expressing the Nb-Slmb fusion, illustrated the specificity of this 
degrading system, as it caused no deleterious, off-target effects to the development of fly 
embryos into adulthood (Caussinus et al., 2012). The deGradFP method can be further 
refined, by fusing auxin-inducible degron (AID) to the Nb fragment instead of an F-box 
protein, thereby requiring auxin binding for the recruitment of Cullin E3 ligase (Daniel et al., 
2018): This exploits Nb selectivity toward target proteins to facilitate conditional protein 
degradation, allowing for temporal functional studies of proteins in cell development, growth, 
and repair (Daniel et al., 2018). For proteins that are linked with regulation of cell growth and 
differentiation (e.g. TRIB proteins), AID-Nb and deGradFP technology may be the way to 
learning/validating its functional role in specific cells at specific stages of growth, and how 
increased TRIB1/2/3 degradation may affect the pathogenesis of certain diseases to give an 
insight of possible therapeutic approaches.  
4.4 Conclusion 
In conclusion, this study was successful in determining whether the yeast display system, in 
conjunction with flow cytometry, is capable of being used as a tool for the rapid 
characterisation of TRIB1-Nbs. Although no new TRIB1-Nbs were discovered to be a better 
binder than the known TRIB1-binder (Nb2.011), this study did reveal important aspects of 
this method that could be accounted for/improved upon for TRIB-Nb characterisation in the 
future. It is important to consider the present non-specific binding between TRIB proteins to 
yeast, as this characterisation method was dependent on fluorophores intensity (for detecting 
Nb expression and TRIB1 binders) to generate MFI for analysis. This study was able to show 
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that the approximated TRIB1-Nb characteristics (affinity and specificity), observed using the 
yeast display method, was comparable to ITC. Hence, as an initial step in the discovery 
pipeline of TRIB-specific Nbs, this method was sufficient in screening the affinity and 
specificity characteristics of the tested TRIB1-Nbs in this study. Furthermore, this method 
may prove to be invaluable in speeding up the Nb discovery process of all human TRIB 
homologues from a naïve Nb-library, by allowing rapid, initial characterisation screens. This  
can narrow down the number of potential Nbs into a smaller Nb panel with desirable KD 
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Appendix A: Reverse time course Nb induction of  S. cerevesiae (yeast clone Nb2.011) 
between 24-48 hours , under galactose supplemented pH6 yeast media. Nbs were labelled 
with αHA-PE, and MFI was measured using Guava ExpressPlus and analysed using FlowJo 
software. GraphPad Prism 8.4.3 was used to generate statistical analysis (n=3) using a one-
way ANOVA, with Dunnett’s post-hoc test (p < 0.05).   1. Shows 1/3 induction replicate 
example of PE histograms made in FlowJo from the 24-, 36-, 48- hours induction flow 
cytometry data measured from Guava ExpressPlus. 2.  A table showing the raw data of  PE  
MFI gathered from FlowJo analysis which represents the level of Nb-expression in Nb-
expressing yeast population.  3.  A table showing the data of Nb-expressing  yeast population 
gathered from FlowJo analysis, that was normalised for background PE signalling using the 
unlabelled control. 4. A table showing the results of the one-way ANOVA test performed on 
the PE MFI data from Appendix A.1 & A.2. 5. A table showing the results of the one-way 









Appendix B: Optimisation of selection buffer for the flow cytometric characterisation of 
TRIB1-Nbs. Standard selection buffer was supplemented with various concentrations of 
reagents to minimise non-specific binding of yeast to FITC labelled TRIB1 proteins. 1. Dot 
plots of different yeast clone populations (both un-induced and induced to express Nbs) 
shows consistent non-specific binding of yeast to TRIB1-FITC, highlighted by red boxes 
(Q1). 2-3. Shows dot plots of un-induced yeast clones incubated with TRIB1-FITC, using 
standard and supplemented selection buffers, with non-specific binding highlighted by red 
boxes: Nb5.018 (negative control) shown in the first row, and Nb2.011 (positive control) 
shown in the second row. 4. Tables showing the raw data gathered from flow cytometric data 
exemplified by Appendix B.2 (n=3). 5. Tables showing the raw data gathered from flow 
cytometric data exemplified by Appendix B.3 (n=3). 6. Tables showing the results of the one-
way ANOVA test performed on the data from Appendix B.4 (n=3). 7. Tables showing the 
















Appendix C: Flow cytometric compensation of FITC spillover into the PE channel. To 
characterise the affinity and specificity of TRIB1-Nbs, a compensation matrix to correct the 
FITC fluorescence spillover to the PE fluorescent channel was made and applied in FlowJo. 
This minimised potential false positive TRIB1-binding results. The compensation matrix was 
made using an unlabelled control, a FITC only control (480 nM TRIB1-FITC, no Nb-PE 
labelling) and a PE only control (Nb labelled with PE, no TRIB1-FITC). 1-2. Shows 
examples of dot plots before and after application of compensation matrix to FITC only 
controls of TRIB1-Nb yeast clones characterised in this project: After compensation, the 








Appendix D: Affinity characterisation of TRIB1-Nb yeast clone controls via yeast 
surface display system and flow cytometry. Dot plots representing an induction replicate of 
Nb binding results to TRIB1-FITC (titrations of 0-480 nM) were generated in FlowJo – 1. 
Nb5.018 (negative control) and 2. Nb2.011 (positive control). A quadrant gate was set using 




Appendix E: Affinity characterisation of TRIB1-Nb yeast clones Nb2.012 and Nb2.029 
via yeast surface display system and flow cytometry. Dot plots representing an induction 
replicate of Nb binding results to TRIB1-FITC (titrations of 0-480 nM) were generated in 
FlowJo – 1. Nb2.012 and 2. Nb2.029. A quadrant gate was set using an unlabelled control, to 




Appendix F: Affinity characterisation of TRIB1-Nb yeast clones Nb2.031 and Nb2.038 
via yeast surface display system and flow cytometry. Dot plots representing an induction 
replicate of Nb binding results to TRIB1-FITC (titrations of 0-480 nM) were generated in 
FlowJo – 1. Nb2.031 and 2. Nb2.038. A quadrant gate was set using an unlabelled control, to 




Appendix G: Affinity characterisation of TRIB1-Nb yeast clones Nb2.049 and Nb2.060 
via yeast surface display system and flow cytometry. Dot plots representing an induction 
replicate of Nb binding results to TRIB1-FITC (titrations of 0-480 nM) were generated in 
FlowJo – 1. Nb2.049 and 2. Nb2.060. A quadrant gate was set using an unlabelled control, to 




Appendix H: Affinity characterisation of TRIB1-Nb yeast clones Nb2.066 and Nb2.074 
via yeast surface display system and flow cytometry. Dot plots representing an induction 
replicate of Nb binding results to TRIB1-FITC (titrations of 0-480 nM) were generated in 
FlowJo – 1. Nb2.066 and 2. Nb2.074. A quadrant gate was set using an unlabelled control, to 




Appendix I: Raw data of affinity characterisation of TRIB1-Nbs using  FITC mean 
fluorescence intensity (MFI) from flow cytometric analysis of yeast surface display 
system. In FlowJo, the FITC MFI was calculated from the Nb-expressing (Nb Pos) 
population. 1-14. Shows table of flow cytometry analysis of affinity characterisation 
experiments exemplified by Appendices D-H, with each separate experiment (represented by 
row) run through with the negative control, Nb5.018. 15. Shows table of flow cytometry 
analysis of second affinity characterisation (ran with Nb5.18) of Nb2.038, Nb2.049, and 








Appendix J: Determining presence of TRIB1-Nb binding to TRIB2 proteins using  FITC 
mean fluorescence intensity (MFI) from flow cytometric analysis of yeast surface 
display system. Nbs expressed on the surface of S. cerevesiae were labelled with αHA-PE 
then incubated with 200 nM TRIB2 labelled with FITC. As a measure of Nb binding TRIB2, 
FITC MFI was measured using Guava ExpressPlus and analysed using FlowJo software 
(n=3). 1. Shows dot plots of flow cytometry data: The first row is an example of the labelling 
controls performed for each Nb tested, using Nb2.011; the second row shows 1/3 induction 
replicates performed to determine whether TRIB1-Nbs (Nb2.011 – positive control, Nb2.038, 
Nb2.066) had any affinity to bind TRIB2; Nb5.018 was used as a negative non TRIB2 
binding control. The 3 TRIB1-Nbs tested were shown to have some affinity to bind TRIB2 at 
200 nM. 2. A table showing the raw data of FITC MFI generated from the Nb-expressing (Nb 
Pos) population, representing TRIB1-Nb binding TRIB2 proteins. 3. Shows a column graph 
of TRIB2 binding TRIB1-Nbs, generated using GraphPad Prism8.4.3, with mean and SD 






Appendix K: Competition assay to determine the specificity of TRIB1-Nb over TRIB2 
using FITC mean fluorescence intensity (MFI) from flow cytometric analysis of yeast 
surface display system. Nbs expressed on the surface of S. cerevesiae were labelled with 
αHA-PE then incubated with a fixed concentration of TRIB1-FITC at 200 nM against 
increasing molar ratio of unlabelled TRIB2 proteins (0X, 1X, 5X, 10X). As a measure of 
affinity, FITC MFI was measured using Guava ExpressPlus and analysed using FlowJo 
(n=3). 1. Shows dot plots of 1/3 induction replicates performed to determine the specificity 
of TRIB1-Nbs (Nb2.011, Nb2.038, Nb2.066). 2.Shows dot plots, an example of the labelling 
controls performed for each Nb tested, using Nb2.011.  3. A table showing the raw data of 
FITC MFI generated from the Nb-expressing (Nb Pos) population, representing TRIB1-Nb 
binding to TRIB2 under increasing molar ratio concentrations of TRIB2. 4. A table showing 
the results of a one-way ANOVA with Dunnett’s post-hoc test performed on competition 
assay data from Appendix K.2 (normalised to mean Nb5.018 data to account for non-specific 
binding), using GraphPad Prism 8.4.3. 
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